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Misidentification of transthyretin and immunoglobulin variants by proteomics due
to methyl lysine formation in formalin-fixed paraffin-embedded amyloid tissue
Proteomics is becoming the de facto gold standard for identifying amyloid
proteins, and is now used routinely in a number of centres. The technique is
compound-class independent and offers the added ability to identify variant and
modified proteins. We re-examined proteomics results from a number of
formalin-fixed paraffin-embedded amyloid samples, which were positive for
transthyretin (TTR) by immunohistochemistry and proteomics, using the Uniprot
human protein database modified to include TTR variants. The amyloidogenic
variant, V122I TTR was incorrectly identified in 26/27 wild type and non-V122I
variant samples due to its close mass spectral similarity with the methyl lysine
modified WT peptide [126KMe]105-127 (p.[146 KMe]125-147) generated during
formalin fixation. Similarly, the methyl lysine peptide, [50KMe]43-59 from
immunoglobulin lambda light chain constant region was also misidentified as
arising from a rare myeloma-derived lambda variant V49I. These processing-
derived modifications are not present in fresh cardiac tissue, non-fixed fat nor
serum and do not materially affect the identification of amyloid proteins. They
could result in the incorrect assignment of a variant, and this may have
consequences for the immediate family who will require genetic counselling and
potentially early clinical intervention. As proteomics becomes a routine clinical
test for amyloidosis, it becomes important to be aware of potentially confounding
issues such as formalin-mediated lysine methylation, and how these may
influence diagnosis and possibly treatment.
Keywords: Amyloidosis, formalin, immunoglobulin, proteomics,
transthyretin, variant.
Abbreviations. FFPE: formalin-fixed paraffin-embedded; CID: collision induced
dissociation; IHC: immunohistochemistry; KMe-WT: methylated wild type; LCMS:
liquid chromatography-mass spectrometry; TTR: transthyretin, WT: wild type.
Introduction
Amyloidoses are protein misfolding diseases in which normal circulating globular
proteins form fibrillar deposits in tissues and organs resulting in structural damage[1].
There are over thirty proteins which form such amyloid deposits and cause the disease
[2]. Diagnosis and treatment of patients with amyloidosis is predicated on the correct
and accurate identification of the amyloid fibril protein. Classically,
immunohistochemistry (IHC), using a range of panel of monospecific antibodies against
known amyloid-forming proteins, has been the most common technique available for
typing amyloid in formalin-fixed paraffin-embedded (FFPE) tissues [3,4]. The
technique is reproducible, but requires experienced staff for both the experimental
procedure and the interpretation of the data, and, in up to 30% of cases IHC fails to
confirm the type of amyloid. Other approaches such as immuno-electron microscopy
have also shown good specificity and sensitivity in diagnosing amyloidosis [5],
although access to equipment and trained operators may not be available in all
diagnostic centres. As with all antibody-based approaches, specificity is dependent on
the quality and availability of suitable antibodies. The advent of laser dissection of
FFPE tissue, coupled with mass spectrometric based proteomic analysis as pioneered by
Ahmed Dogan and colleagues at the Mayo Clinic [6-10], has been shown to be a
powerful and complementary tool for amyloid identification. The approach is now
being applied successfully at a number of other centres [11-17].
Gene mutations, encoding variant proteins, can have a marked effect on the inherent
amyloidogenicity of many proteins, and this can lead to the development of
amyloidosis. An up-to-date summary of all amyloid protein mutations can be found at
http://amyloidosismutations.com/attr.html. Mass spectrometric proteomic approaches
are compound-independent, and are ideally suited for the detection and identification of
variant proteins. This has been recognised by Dasari and colleagues [18] who have
developed a proteomics informatics workbench for identifying amyloid variants. There
are over 100 point mutations in the transthyretin (TTR) gene resulting in the expression
of variant proteins, many of which are more amyloidogenic than the wild type (WT)
TTR [19,20]. These mutations cause autosomal dominant hereditary systemic ATTR,
presenting in adult life as so called familial amyloid polyneuropathy/cardiomyopathy.
The clinical phenotype is predominantly one of peripheral and autonomic neuropathy
with variable involvement of the heart, kidneys, eyes, and gut. The disease progresses
inexorably for 10-15 years and is inevitably fatal.
By far the most common causative mutation encodes the Val30Met substitution
and the cases are largely localised to discrete foci in northern Portugal, northern Sweden
and specific localities in Japan, as well as the descendants of individuals from these
areas living elsewhere [20]. The genetic polymorphism encoding the V122I
substitution, is the second most pathogenic polymorphism in African Americans after
sickle cell disease and causes cardiac TTR amyloidosis in the elderly [21,22].
Normal WT TTR is inherently amyloidogenic and it has now been demonstrated
that cardiac TTR amyloidosis can develop from the WT protein particularly in the
elderly. This leads to arrhythmias, heart failure with preserved ejection fraction and
death [23,24], conditions which were hitherto commonly attributed to coronary artery
disease and other prevalent cardiac conditions. Although, it is not clear what initiates
the process of WT TTR amyloid deposition, and we conjectured that the acquisition of
low level clones expressing an amyloidogenic variant could act as a source of TTR
amyloid seeds. In this study we re-examined proteomic data from a number of TTR
amyloid positive FFPE tissues using a modified Uniprot database to include a number
of TTR variants: clonal variants were not detected but we observed the presence of N-
methylated TTR peptides derived from formalin fixing, and which had been
misidentified in the database search as the V122I (p.V142I) variant. Methylated
peptides were also observed in biopsies from lambda patients, resulting in incorrect
variant assignments, and also in proteins from other FFPE samples.
Methods
Samples
Formalin-fixed paraffin-embedded tissue are regularly collected as part of routine
diagnostic procedures from patients attending the UK NHS National Amyloidosis
Centre and are also received from other centres for immunochemical and proteomics
analysis. Thirty five samples of FFPE tissue were randomly selected from patients
diagnosed with ATTR amyloidosis and which had been identified as containing TTR
amyloid by Congo red staining [25,26], immunohistochemistry using a panel of
antibodies, genotyping and proteomics analysis [27,28]. Twenty seven samples were
from cardiac tissue, with one sample each of bone marrow, GI tract and penile, two
bladder samples and three carpal tunnel samples. The genomic DNA for TTR was
sequenced as WT (n=22), V122I (5), T60A (2) and one each of G6S, V20I, V30M,
D39V, E89K and H90D. Five non-genotyped TTR samples and twelve non-TTR
amyloid controls (2 AL (), 6 AL (), 2 AFib and 2 AApoA1) were also analysed.
Seven non-formalin-treated fat aspirates from ATTR patients plus six non-ATTR
controls, 5 AL () and 1 AL (), together with a four fresh unfixed ATTR cardiac tissue
samples, were also obtained as controls for formalin-mediated TTR methylation. In a
separate study, designed to investigate the variation in immunoglobulin lambda light
chains, a further thirty two FFPE tissues were also collected from seventeen lambda
patients and fifteen other non-lambda amyloidosis controls (2 AApoA1, 6 AFib, 4 AL
() and 3 ATTR). Patient data are summarised in Table 1 and supplementary Tables S1
and S2.
Proteomic analysis
Amyloid-positive FFPE samples were micro-dissected and captured using the Zeiss
Palm Microbeam instrument and were prepared for proteomics analysis using the
method of Rodruiguez and colleagues [29]. Similar areas of Congo red positive tissue
dissectates (6µm thick) were extracted into 10 mM Tris in MilliQ water containing
1mM EDTA and 0.002% Zwittergen at 99°C for 1.5 hours followed by sonication for 1
hour. They were treated with Trypsin Gold (2.25 μg/sample) overnight at 37°C and then 
reduced with dithiothreitol (50 μg) at 99°C for 5 minutes. The buffer was removed 
under vacuum and peptides re-suspended in 0.1% trifluoroacetic acid in water with
sonication; any remaining solids were removed by centrifugation (10,000g for 10
minutes). Non-fixed cardiac tissue was divided into two pieces; one piece was fixed and
stained with Congo red to confirm the presence of amyloid and the other piece was
washed and digested as above. Fat aspirates were washed with PBS and then treated in
the same way as FFPE samples; a separate smear was taken to confirm the presence of
amyloid. Digests were trapped on a Dionex AcclaimPepMap100 C18 cartridge (5mm x
300 µm ID; 5µm particle size, 100 Å pore size, Thermo Scientific) column and then
chromatographed on a packed tip reverse phase column (100 µm ID x 150 mm bed, 5
µm C18 packing; Nikkyo Technos Company Ltd, Tokyo, Japan) using a
nanoACQUITY ultraperformance liquid chromatography (UPLC) system (Waters,
Elstree, Hertfordshire WD6 3SZ) coupled to a Velos Orbitrap mass spectrometer
(Thermo Scientific, Bremen, Germany). Elution was undertaken at 400nl/min with a 44
min linear gradient of acetonitrile:water:formic acid (5:95:0.1 – 60:40:0.1 v/v/v).
Optima LCMS grade water, formic acid and trifluoroacetic acid were obtained from
Fisher Scientific, UK. Chromasolv LC-MS acetonitrile was obtained from Honeywell
Research Chemicals, Riedel-de Haën, Germany. The chromatographic system was
washed between each sample using a protocol (adapted from Fang [30]) to include
separate washes of 10% formic acid, 0.1% trifluoroacetic acid, 1% ammonia in 50%
acetonitrile, 80% methanol and 80% acetonitrile in water. A control blank was run prior
to each sample to confirm the absence of any carryover. The UPLC eluate was passed
directly into the Velos nanospray ion source which was operated in the positive ion
mode. A full MS scan (m/z 400–2000) was acquired with a maximum injection time of
50ms, and the 20 most intense ions with a count threshold >500 were selected for
collision induced dissociation (CID). The lock mass was set at m/z 445.120024. The
normalised collision energy was 35, with an isolation width of 2 and dynamic exclusion
of 20; singly charged ions were excluded. Data were analysed using Mascot software
(Matrix Science, London, UK) using the Swissprot human database. Search parameters
were: precursor mass tolerance of 10 ppm, 0.6 Da for collision induced dissociation
(CID) fragments, trypsin (and occasionally semi-trypsin) as the proteolytic enzyme, two
missed cleavages, included charge states +2, +3 and +4 and a significance level at
p<0.05. Methionine oxidation, and later N-methyl lysine, were included as variable
modifications. A separate Mascot search was then undertaken using a database prepared
by appending a selection of variant TTR variants (p.V50M, p.S72P p.T80A, pV142I) or
the Kabat [31] immunoglobulin lambda collection
(ftp://ftp.ebi.ac.uk/pub/databases/kabat/) to the human Uniprot database. Theoretical
CID spectra for manual spectral comparison were generated using Protein Prospector
(http://prospector.ucsf.edu/prospector/mshome.htm: UCSF Mass Spectrometry
Facility). Three FFPE samples, digested in our laboratory, were also analysed at CNR-
ITB, Milan using a nanoLC platform coupled to a Thermo Q-Exactive mass
spectrometer with data handling by Proteome Discoverer v 1.4 based on the Sequest
algorithm. Sequence numbering will be reported for the mature protein unless otherwise
stated. Raw mass spectrometric data are available on request to the corresponding
author
Preparation of recombinant V122I TTR
Recombinant V122I TTR was expressed using a pET3a vector containing the full-
length cDNA for human V122I TTR in E. coli BL21 super competent cells and purified
as previously reported [32].
Extraction of TTR from serum
TTR was immunoprecipitated from serum collected from a V122I patient and from two
normal healthy male subjects (age 29 and 64), one of whom had previously been
genotyped as WT TTR. A polyclonal affinity-purified sheep anti-human TTR antibody
(Binding Site, Birmingham, UK) was buffer-exchanged into PBS using biospin columns
(Bio rad laboratories, Herts UK) and incubated overnight at 4C with CNBR activated
sepharose 4B beads (Sigma, prepared following manufacturer’s instructions). The beads
were then blocked with 0.2 M glycine in PBS and extensively washed with PBS (25ml)
followed by 4 x 5ml washes with 0.1M acetate buffer in 0.5 M NaCl (pH4) and then 0.1
M sodium bicarbonate buffer in 0.5 M NaCl (pH8);the beads were re-equibrated with
20ml PBS. Serum (100ul) was added to the anti-TTR beads and incubated for 2 hours at
room temperature and then washed with PBS (10ml). TTR was eluted from the beads
with 200ul of 0.2M glycine buffer pH2. The eluates were neutralised with 1M Tris HCl
pH 8, dialysed in PBS for 2 days followed by trypsin digestion and proteomics analysis.
Ethical approval
Samples were collected and analysed as part of routine clinical examination. Informed
consent was obtained from all patients and clinical care was in accordance with the
Declaration of Helsinki
Results
Apparent identification of V122I TTR in FFPE tissues
Thirty five FFPE tissues were selected where transthyretin had been identified as the
amyloid protein by immunohistochemistry and proteomics. DNA sequencing identified
homozygous WT TTR in the majority of samples, together examples of G6S, V20I,
V30M, D39V, T60A, E89K, H90D and V122I variants. Twelve non-TTR control
samples were also selected at random: these were 6 AL (), 2 AL (), 2 AFib and 2
AApoA1 and did not show proteomics evidence for TTR. The proteomics data from
each sample was re-analysed using Mascot together with an extended database
containing a number of potential TTR variants appended to the Uniprot database.
Unexpectedly, both WT TTR and the V122I variant were identified by the presence of
the 105-127 (p.125-147) C-terminal fragment in 31/35 samples, including known V122I
and non-V122I variants. Other C-terminal fragments including 105-126 were also
present in some samples. One sample generated only the WT [122I] 105-127 peptide
and was included in further analysis, however three samples failed to show coverage for
the residues 105-127 (encompassing the 122V position) and were excluded
(Supplementary Table 1), leaving thirty two samples for further analysis (Table 1). It is
not uncommon to observe variable protein coverage, due to limited trypsinisation, poor
peptide extraction or sample-mediated ion suppression. Even with strongly Congo red
positive samples we occasionally observe low or absent amyloid and signature protein
scores, even when the total protein recovery is high. The [122I]105-127 variant peptide
was associated only with TTR amyloid, and was not detected in any of the non-TTR
amyloid controls. It is clear, however, that the [122I] peptide cannot arise from the WT
protein, implying its presence is artefactual.
Two V122I isobaric peptides identified
The chromatographic behaviour and mass spectra from each of the thirty two samples,
where the 105-127 WT peptide was observed were examined manually: the apparent
122I-containing 107-125 fragment eluted <5s after the equivalent WT peptide
[122V]105-127 in the all WT and non-V122I variant samples, generating molecular ion
species (MH22+, m/z 844.94) and an CID spectrum which was essentially homologous
with that from the WT peptide. The amount of this peptide, estimated from relative ion
intensities, varied from 0-45.1% of that of the WT peptide (Table 1). This peptide was
also present in 4/5 samples from patients with a confirmed V122I variant, however, in
each of these cases, a second peptide was also identified by Mascot as [122I]105-127. It
eluted ~30s later than the WT peptide (Figure 1), and generated a more intense
molecular ion signal which was approximately equi-intense with the corresponding WT
peptide. This peptide was only observed in authentic V122I samples. Although the CID
mass spectrum appeared similar to that of the earlier eluting component, the different
chromatographic retention times showed that these two peptides were structurally
dissimilar.
Analysis of recombinant V122I
Proteomics analysis was then undertaken on authentic recombinant V122I TTR,
dissolved either in buffer or in human serum. The characteristic [122I]105-127 peptide
eluted ~30s after the equivalent WT peptide, [122V]105-127 co-eluting with, and
generating indistinguishable mass spectra from, that obtained from both the V122I TTR
patients. The earlier eluting 122V-like component present in the majority of the FFPE
samples was clearly not the expected variant and appeared to be a 14 homologue of
the WT peptide.
Identification of N-methyl lysine modified peptides
Closer examination of the CID spectra of authentic [V122]105-127 peptide and the 14
WT homologue showed that, although the spectra were essentially indistinguishable
above m/z 700 (Supplementary Figure S1) , there were clear differences at lower
masses (Figure 2). Authentic [V122I]105-127 generated y ions at m/z 373.31 (..PKE),
487.31 (…NPKE), 588.40 (…TNPKE) and 701.46 (…ITNPKE) whereas the earlier
eluting isomer produced homologues (14u) at m/z 387.46, 501.44 and 602.31, with
m/z 701.46 common with the V122I ion. These data are consistent with the presence of
N-methylated lysine in the WT peptide, YTIAALLSPYSYSTTAVVTNPKMeE,
[126KMe]105-127 (Figure 3); here the y series ions > m/z 700 are indistinguishable as
...ITNPKE and …VTNPKMeE (m/z 701.46), and longer y ion fragments, are isobaric.
Homologous b ions for YTIAALLSPYSYSTTAVI.. and YTIAALLSPYSYSTTAVV..
at m/z 1916.0 and 1902.0 arising from V122I and KMe peptides respectively were
further evidence for the reported sequences. The mass range (m/z 400-2000) of these
spectra precluded the identification of other characteristic low and high mass ions.
Re-searching the spectra using the TTR variant database with Mascot using
methyl lysine as a variable modification identified [126KMe]105-127 in 26/27 non-
V122I samples, with retention times similar to that of the non-methylated WT peptide.
In only one case was the KMe-WT peptide below detection in the selected ion mass
chromatogram. Both the [126KMe] WT TTR and V122I TTR were identified in the five
samples from V122I patients, including one (patient 10), where the methylated peptide
wasn’t detected by LCMS. There were 28 positive Mascot queries for KMe-WT and
V122I in this group, however, many of the same queries, with different peptide scores,
were used for both sets of identities: KMe-WT was identified in only one sample, V122I
in 8 samples, with both proteins identified in 19 samples. The retention times associated
with these 19 scored peptides covered both the methylated and variant peptide region
and were insufficient to allow differentiation; only the retention times determined from
the LCMS selected ion chromatograms allowed confirmation of the presence of KMe-
WT and V122I TTR in these samples. The corresponding 122I methylated peptide
could also be detected in 3/5 samples, eluting ~0.4s later than the 122I peptide. Other
methylated TTR peptides (35-48, 49-70 and 49-76) were present in some samples
together with methylated proteins including the amyloid signature protein, serum
amyloid P component. Analysis of non-TTR FFPE control samples also showed the
presence of N-methylated proteins, including Ig lambda, however this seemed to be
more variable with no evidence of methylation in some cases.
Analysis of fresh tissue
Data from thirteen non-formalin treated fat aspirates obtained in our clinic and a four
fresh ATTR cardiac tissue samples were also re-analysed for the presence of methyl
lysine peptides. There was no evidence for lysine methylation in either the amyloid or
amyloid signature proteins in any of these samples, nor, indeed in any other proteins
apart from some occasional low scoring (<10) queries ascribed to haemoglobin
peptides. Three TTR-positive fat samples did not show coverage of the 105-127 region
and were then excluded from further analysis. The authentic variant [122I]105-127
peptide was identified both from its retention time, eluting 27s after the WT peptide,
and its CID mass spectrum in the single fat sample from a V122I patient.
To confirm that [126KMe]105-127 peptide was not derived from a circulating
methylated protein, TTR was extracted by immunoprecipitation from serum from a
genotyped WT patient and two healthy controls. In each case only WT TTR was
identified with no evidence for [126KMe]105-127 or other methylated peptides
These data indicated that the V122I variant, apparently present in most of the
FFPE samples examined, had been misidentified due to the close spectral similarity
with the [126KMe] homologue of the WT peptide [V122]105-127. Zhang and colleagues
[33] have recently shown that formalin fixing can cause lysine methylation, and our
data is entirely consistent with their report.
Immunoglobulin light chain lysine methylation
The presence of immunoglobulin light chain peptides in non-AL amyloidosis patient
samples is not uncommon [34], and in an unrelated study we were examining ways to
increase confidence in the proteomics of AL amyloidosis samples by appending the
Kabat collection of lambda and kappa light chain sequences to the Uniprot human
database. In many cases of light chain amyloid, extra variable region peptides could be
identified and this was helpful in confirming the amyloid type. Using this extended
database we noted that a 14 peptide, ADSSPIKAGVETTTPSK, corresponding to an
uncommon IV variant at residue 49 of the lambda constant region ([49I]44-60) from
a human myeloma cryoglobulin [35] could be identified by Mascot in 11/17 AL ()
patient samples and also in 2/15 non-AL () controls (supplementary Table S2) where
lambda was a significant contaminant. The structure of this variant is identical with the
Lac2 lambda constant region but lacks the N-terminal glycine at the junction with the
variable region; for reasons of clarity the WT numbering is used. The presence of
[49I]44-60 was unexpected as this region is not normally detected in the WT protein
since there is a facile tryptic cleavage at K50 generating two small peptides outwith the
normal acquisition mass range of our instrument. Initially we considered whether low
level clonal production of the myeloma protein was responsible for seeding lambda
deposition, however, based on our experience with formalin-modified TTR we re-
examined the data for the samples originally identified as the lambda variant using N-
methyl lysine as a variable modification in a Swissprot database search. All were
identified as containing the lambda (Lac2) constant region methylated peptide,
[50KMe]44-60 together with other lambda methyl lysine peptides, notably 22-43, 66-80
and 84-98. A number of methyl lysine containing peptides arising from non-
amyloidogenic proteins were also identified. Differentiation between the 50KMe and 49I
peptides is difficult since their CID spectra are very closely related with only two
characteristic b6 and y7 ions, m/z 557.257, 1132.621 and m/z 571.272, 1118.605
respectively, distinguishing the two peptides. There was no evidence for either of the
characteristic 49I ions in any of the spectra. In contrast, [50KMe]44-60 was confirmed in
6/15 samples by the presence of one or both of its characteristic ions (Figure 4). In the
remaining samples there was no ion coverage for the 49I/50KMe region in the mass
spectra and it was therefore not possible to differentiate between the putative variant
and the methylated WT peptide. However, since trypsin cleavage at methyl lysine is
slow, and a simple VI change would not be expected to alter sensitivity of a peptide
to trypsin, the presence of the methylated [50KMe]44-60 is far more likely than the
equivalent variant [49I]44-60 peptide with an internal unmodified lysine. Indeed, the
cleavage after 50K in wildtype lambda is facile that it is rare to see coverage of this
region. These data are fully consistent with the conclusion that the 14 peptide
originally identified as a 49I variant in lambda samples was actually the formalin-
derived 50KMe WT product. Protein coverage for a lambda sample as determined by a
Mascot search using Swissprot (with and without methyl lysine as a variable
modification) or Kabat database is shown in Figure 5.
Not all of the lambda samples were originally identified as containing the
variant/KMe peptides suggesting that the amount of formalin-mediated methylation is
variable and differs from sample to sample, and possibly even within an individual
biopsy. A further set of 12 lambda samples, individually dissected from a single biopsy
over a period of 12 months were examined for the presence of the variant/KMe peptide.
All were positive for 50KMe peptide based on the molecular mass and partial sequence.
Manual examination of the spectra gave no evidence for any 49I characteristic ions,
although was only possible to confirm the presence of 50KMe in one sample through the
presence of its characteristic CID ions. Three of these digested samples were then
analysed at CNR-ITB, Milan using a Thermo Q-Exactive platform; each showed
evidence for m/z 1132.63 with partial sequence …KMeAGVETTTPS….
(Supplementary Figure S2) confirming our initial identification.
These data on samples of immunoglobulin lambda light chain amyloid are
further evidence that the formalin fixing of human biopsies taken for clinical purposes
results in the formation of N-methyl lysine, and that this can lead to the
misidentification of a variant.
Discussion
Over the past four years we have used the proteomics approach developed at the Mayo
Clinic and have examined over 1500 FFPE samples from both patients attending our
clinics and also referred biopsy samples. Our general experience is that proteomics
complements, but does not always supplant, immunohistochemical analysis. Our 2015
audit showed 70% concordance between the proteomics and immunohistochemistry
data. Mass spectrometric approaches are not limited by compound class, and this is
particularly beneficial when identifying variant proteins [36]. There are numerous
mutations associated with the genes for the amyloidogenic proteins, in particular with
ApoA1, transthyretin and fibrinogen A, many of which result in the expression of
variant amyloidogenic proteins and consequent different clinical presentations. For
example, the most common form of familial amyloid polyneuropathy is caused by the
V30M TTR whereas the V122I variant, which is common in African Americans causes
cardiac ATTR amyloidosis in the elderly. In contrast, the T119M mutation appears to
confer protection against TTR amyloidosis. There is clearly some clinical benefit in
identifying these variants as part of a routine proteomics approach [18].
When we re-examined the proteomics data from FFPE biopsies from patients
diagnosed with TTR amyloidosis using our variant database, it was surprising to find
that V122I TTR was identified in so many samples, and it soon became clear that this
was a false identification. Manual examination of the mass spectra indicated the
presence of a methyl lysine homologue of the WT peptide 105-127. The
chromatographic retention times and mass spectra were consistent with the presence of
[126KMe]105-127 and not [122I]105-127 in these samples, and this was confirmed by a
subsequent Mascot search including methyl lysine as a variable modification. The
absence of [126KMe]105-127 in unfixed tissue, fat aspirates and serum was consistent
with its generation by formalin fixing. We also observed methylated derivatives of SAP
and a range of other proteins in FFPE tissue, so this effect was not limited to the
amyloidogenic protein. We were aware of the range of modifications which can arise
through formalin fixation [37,38], however, it was only following the report by Zhang
and colleagues [33] that it became clear that lysine methylation was a major
modification induced by FFPE tissue processing. They cautioned this could skew the
results when studying biological methylations: clearly it can potentially affect clinical
diagnosis as well. The amount of [126KMe]105-127 in different samples varied from 0-
45.1% of the WT protein and this was irrespective of tissue source, although we note
that this is an estimate based on ion channel intensities and assumes an equivalent
ionisation efficiency. We receive FFPE tissues from a number of hospitals throughout
the world, and so it is not possible to account for, or indeed control, the conditions
under which samples are fixed, and consequently the amount of N-methylation that can
occur. Similarly with the lambda samples, the identification of an obscure variant in the
constant chain was not expected, and the presence of a methyl lysine was postulated. In
most cases it was not possible to distinguish the 49I and 50KMe peptides. The absence of
any mass spectra unequivocally defining [49I]53-59 and the clear identification of the
50KMe peptide in a few samples strongly suggests that formalin-mediated methylation
has occurred. Our mass spectrometric data were generated on a Velos Orbitrap. High
energy collision spectra, obtained on a different platform, the Q-Exactive Orbitrap
machine, in collaboration with colleagues at CNR-ITB, Milan, allowed us to more
easily distinguish between the spectra of the two 14 lambda peptides and confirm the
presence of N-methylated peptides.
In a recent review covering the progress and potential of proteomics in cardiac
amyloidosis, Lavatelli and Merlini [39] quite correctly stated that “amyloidogenic
mutations can be confirmed if the variant peptide is visible and the variant sequence is
deposited in the sequence repositories”; it is, of course, a pre-requisite that the variant
peptide can be unambiguously identified. We normally use Mascot, and less commonly
Scaffold/X! Tandem, as our preferred search engine, although others recommend
multiple engines to enhance protein identification both generally [40,41] and in
particular for amyloid identification [6]. The close proximity of a methylated lysine to
an apparent 14 variant such as VI (as in these samples), or for example, GA, will
always result in an identical parent ion mass and very similar CID fragment ions. There
is no reason to believe that other search engines or a combination of search methods
would have eliminated the problem of misidentifying FFPE methylation products as
variants. As the separation in the peptide between the methylated lysine and apparent
14 variant increases then it becomes easier to distinguish between the CID spectra, and
there is less chance of misidentification.
Once the effects of formalin fixation are recognised, it is simple to include
methyl lysine or other derivatives as a variable in the search. Since the methylated WT
and V122I variant peptides are chromatographically distinct, LCMS retention times
obtained could be used to increase confidence in the structural assignments. Although
retention times for each scored peptide are available in search outputs, the values
associated with KMe-WT and V122I peptides were similar and it was not possible to
differentiate these peptides without directly examining the raw LCMS ion
chromatograms. The effects of formalin would not be an issue if unfixed tissue were to
be used, however this is not normally collected for routine clinical diagnostics,
particularly if samples are to be sent to a separate referral lab for analysis. Serum has
been examined for amyloid precursors, for example to characterise free light chains
[42,43] and fresh fat aspirates are now routinely available for proteomics analysis
[44,45], although both will always be a surrogate for identifying amyloid deposition in
the target tissue and may fail to identify cases where two distinct types of amyloid are
present in the same tissue [12,46].
Does the misidentification of variants matter clinically? At one level, it doesn’t:
AL amyloidosis will be treated with chemotherapy irrespective of the potential presence
of a rare constant region variant. Of course, should N-methylation also occur in the light
chain variable region, then misidentification could compromise the identification of
light chain clones [47]. Current treatments for ATTR amyloidosis with diflunisal or
tafamidis will still be used for many ATTR patients, however the identification of an
aggressive variant will affect the prognosis and may suggest liver transplant as an
option. It could also have consequences for the patient’s immediate family where
genetic counselling and potentially early clinical intervention may be incorrectly
indicated. Further, recent studies on the mechanism of TTR fibrillogenesis initiated by
proteolytic cleavage [48] have indicated that ligand-mediated inhibition differs for each
variant; it may therefore important to correctly identify the variant when determining a
suitable therapeutic dose.
The potential problems with using proteomics as the sole method for amyloid
typing have also been recognised by Brown and colleagues [49]. In a study on ATTR
amyloidosis they noted that “LC–MS/MS is not sufficient to rule out a pathogenic
mutation in cases of ATTR amyloid, and genetic testing should be performed in most
cases”. We would not disagree: to extend the three legged stool’ analogy (attributed to
Richard Hooker), we would argue that the most robust diagnosis of amyloidosis relies
on the three legs of clinical experience, biochemistry (Congo red staining, IHC and
genetic analysis) and proteomics. Even then, as proteomics becomes a routine clinical
test and we begin to rely entirely on the output from increasingly complex search engine
algorithms, it becomes important to be aware of how unanticipated effects such as
FFPE-mediated methylation can result in variant misidentification and influence
diagnosis and possibly treatment.
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Table 1. ATTR patients’ sample details showing the relative amount of the
formalin-derived KMe-WT 105–127 peptide and the 122I variant peptide.
CT: carpal tunnel, BMT: bone marrow trephine.
Figure 1. Selected ion chromatograms for TTR peptide 105-127 from patients with WT
TTR (2, panel A) or heterozygous WT/V122I TTR (12, panel B). Ion channels are
shown for MH22+ m/z 1245.14, corresponding to the WT peptide (A1 and B1), and also
for the MH22+ m/z 1252.15 which is isobaric for the N-methylated WT peptide,
[126KMe]105-127 (A2) and the 122I variant peptide (B2). In the patient expressing WT
TTR only, the methylated derivative was present and eluted <5s after the WT peptide,
although the intensity was lower. This peptide was also observed in 4/5 of the non-
V122I patient samples. Authentic [122I]105-127 from patient B eluted ~30s after the
WT peptide at 30.6 min, with a similar intensity (B2). It had the same retention time as
the peptide generated from authentic recombinant V122I TTR. There was a small
amount of the methylated WT peptide also present. Ion channels in patients A and B
were smoothed and normalised to the maximum wave image current within the
retention time window of 249,674 and 49, 939 respectively.
Figure 2. Collision induced mass spectrum for 122I[105-127] from a patient confirmed
to exhibit the V122I mutation (A). This peptide eluted ~30s after the corresponding WT
peptide with a mass spectrum which was indistinguishable from that obtained from
recombinant V122I TTR. In samples from non-V122I patients the 14 105-127 peptide
eluted <5s after the WT peptide and generated a similar CID mass spectrum (B),
differing from V122I[105-127] at ion masses below m/z 700. The characteristic y ions
which distinguish the two isobaric peptides are highlighted (*).
Figure 3. Alignment of peptide 105-127 for WT TTR, V122I TTR and 126KMe WT
TTR. The positions of the variant and methylated lysine are arrowed.
Figure 4. Collision induced dissociation mass spectrum of methylated lambda light
chain constant region generated from the molecular ion species, MH22+ m/z 844.94 (A).
The most intense b and y ions for the peptide are labelled*. Expanded regions for the
characteristic b6 (m/z 557.260 and y11 (m/z 1132.62) ions are shown in panel B, and
confirm the presence of the methylated peptide [50KMe]44-60 and the absence of the 49I
variant.
Figure 5. (A) Coverage of lambda constant region from an FFPE bone marrow sample;
Mascot identified peptides are underlined. The region 44–50 (ADSSPVK) was not
identified, in common with most of our lambda samples. (B) By including methyl lysine
as a variable modification in the Swissprot search parameters the methylated peptide
[50KMe] 44-60 was identified. (C) Using an extended Uniprot + Kabat database search,
the rare VI variant was also identified, however examination of the mass spectra
shows that this was an incorrect assignment resulting from formalin-mediated lysine
methylation. The positions of the putative variant and methylated lysine are arrowed.
Supplemental data
Mis-identification of transthyretin and immunoglobulin variants by
proteomics due to methyl lysine formation in formalin-fixed paraffin-
embedded amyloid tissue.
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Table S1: Patient details for TTR control samples, non-genotyped samples and excluded
samples (no WT coverage of TTR 105-127). The methylated peptide [126KMe]105-127
was present only in the five non-genotyped TTR samples but absent in all controls.
__________________________________________________________________
Patient Tissue Gender Age Amyloid Comments
__________________________________________________________________
37 bladder (FFPE) M 75 ATTR non genotyped
38 cardiac (FFPE) M 76 ATTR non genotyped
39 cardiac (FFPE) M 87 ATTR non genotyped
40 cardiac (FFPE) M 85 ATTR non genotyped
41 GI (FFPE) F 83 ATTR non genotyped
42 BMT (FFPE) F 67 AL() FFPE control
43 cardiac (FFPE) F 60 AL() FFPE control
44 cardiac (FFPE) M 64 AL() FFPE control
45 cardiac (FFPE) M 69 AL() FFPE control
46 cardiac (FFPE) M 84 AL() FFPE control
47 GI (FFPE) M 81 AL() FFPE control
48 GI (FFPE) F 80 AApoA1 FFPE control
49 renal (FFPE) M 44 AApoA1 FFPE control
50 renal (FFPE) M 51 AFibA (E526V) FFPE control
51 renal (FFPE) M 60 AFibA (E526V) FFPE control
52 renal (FFPE) M 71 AL() FFPE control
53 skin (FFPE) F 66 AL() FFPE control
54 cardiac (FFPE) M 66 ATTR (T60A) no WT coverage
55 cardiac (FFPE) M 76 ATTR (WT) no WT coverage
56 GI (FFPE) M 69 ATTR (WT) no WT coverage
57 fat F 53 AL() fat control
58 fat F 58 AL() fat control
59 fat M 60 AL() fat control
60 fat F 65 AL() fat control
61 fat F 79 AL() fat control
62 fat M 67 AL() fat control
63 fat F 49 ATTR( I73V) no WT coverage
64 fat F 72 ATTR (V122I) no WT coverage
65 fat M 84 ATTR (V122I) no WT coverage
__________________________________________________________________
BMT: bone marrow trephine, GI: gastrointestinal
Table S2. Patients’ samples used in the immunoglobulin lambda analysis study.
Samples containing the ∆14 44-60 peptide are marked (+).  There was a significant 
level of lambda peptides present in control samples L28 and L29, and these both
showed the presence of the ∆14 peptide. 
Patient Gender Age Amyloidtype
FFPE
tissue
∆14 
peptide
L1 M 59 AL(λ) cardiac + 
L2 M 76 AL(λ) renal + 
L3 M 51 AL(λ) cardiac  
L4 M 75 AL(λ) cardiac + 
L5 M 81 AL(λ) rectal  
L6 F 44 AL(λ) cardiac  
L7 M 66 AL(λ) cardiac + 
L8 M 43 AL(λ) renal  
L9 F 14 AL(λ) skin + 
L10 M 65 AL(λ) cardiac + 
L11 F 41 AL(λ) laryngeal + 
L12 M 77 AL(λ) laryngeal  
L13 M 84 AL(λ) laryngeal + 
L14 F 79 AL(λ) adrenal  
L15 M 51 AL(λ) spleen + 
L16 F 65 AL(λ) laryngeal + 
L17 F 44 AL(λ) laryngeal + 
L18 M 78 AFib (E526V) renal
L19 M 68 AFib (E526V) renal
L20 M 74 AFib (E526V) renal
L21 F 73 AFib (E526V) renal
L22 M 50 AFib (E526V) renal
L23 M 79 AFib (P552H) renal
L24 M 50 AL(κ) skin  
L25 F 73 AL(κ) renal  
L26 F 62 AL(κ) renal  
L27 M 63 AL(κ) rectal  
L28 M 60 AApoAI BMT +
L29 F 79 AApoAI renal +
L30 M 68 ATTR laryngeal
L31 M 65 ATTR cardiac
L32 M 82 ATTR cardiac
BMT: bone marrow trephine
Figure S1. Full MSMS spectra for TTR peptide [122I]105-127 from the authentic
V122I variant (top panel) and the 126KMe methylated wild type peptide formed during
formalin fixing(bottom panel). The spectra are essentially indistinguishable between
m/z 700 and 2000.
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Figure S2. MSMS spectra of m/z 1688.8783+ from three digested lambda samples
analysed on a Q-Exactive instrument. Sequence ions for ..KMeAGVETTTPS.. are
highlighted in red. The characteristic y11 ion (m/z 1132.6) is present in all spectra (see
red asterisk).
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